Skip to content
Agentic OS
Menu

Intelligence / B2B SaaS / Acquisitions / Repligen Corp

M&Acompleted an acquisition (SEC 8-K)6 Oct 2026

Repligen Corp

6 Oct 2026: Completed an acquisition (SEC 8-K) · Pharma and biotech. Recorded in the SEC EDGAR full-text search.

View the source record

Filed
6 Oct 2026
Ticker
RGEN
Role
Completed an acquisition
Sector
Pharma and biotech
Sic
2836
Items
2.01, 7.01, 9.01
Summary
At the effective time of the First Merger (the "First Merger Effective Time"), each share of BioLife's common stock, par value $0.001 per share ("BioLife Common Stock"), issued and outstanding immediately prior to the First Merger Effective Time (other than (i) any shares that were held by BioLife in treasury or owned
Location
Waltham, MA
State
Massachusetts
Country
United States
SEC CIK
730272
Reference
0001193125-26-415015
What this signal means

Integration means consolidating tools and vendors: the buyer re-platforms the target, and an acquired company's stack is reviewed by its new owner.

  1. Completed an acquisition leads with 189 of 292, then Sold assets or a business (82).
  2. 103 added in the 30 days to 19 Nov 2026.
Reach them with AOS

Find the decision makers at Repligen Corp

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this m&a signal, for your approval.

Start free

More in Completed an acquisition

Acquisitions

See all

Source: SEC EDGAR full-text search, data to 19 Nov 2026. Every Form 8-K reporting Item 2.01 (completion of an acquisition or disposition of assets) filed with the SEC in the last 90 days. The role (buyer, company acquired, seller) is read from the filing's own wording, which is quoted on each row. AOS shows what the public record says; it does not verify or endorse the company.